Ylitalo P, Auterinen L, Marttinen A, Koivula T
Int J Clin Pharmacol Res. 1984;4(2):141-4.
The possible competition of isoniazid for the acetylation of sulphadimidine was studied by comparing the degree of acetylation of urine sulphadimidine (1 g orally) in isoniazid-treated and in isoniazid-untreated patients. The former group (isoniazid 300 mg once daily) consisted of 5 slow and 5 rapid acetylators and the latter group of 5 and 6 respective acetylator phenotypes. In all of the 4-8, 8-12 and 12-24 h urine fractions, the acetylation percentage of sulphadimidine and its distribution pattern were practically unaffected by the isoniazid. This suggests that isoniazid therapy does not interfere significantly with the routine acetylator phenotyping by means of sulphadimidine.
通过比较接受异烟肼治疗和未接受异烟肼治疗的患者尿液中磺胺二甲嘧啶(口服1克)的乙酰化程度,研究了异烟肼对磺胺二甲嘧啶乙酰化的可能竞争作用。前一组(异烟肼每日一次300毫克)包括5名慢乙酰化者和5名快乙酰化者,后一组分别有5名和6名相应的乙酰化表型。在所有4 - 8小时、8 - 12小时和12 - 24小时的尿样中,磺胺二甲嘧啶的乙酰化百分比及其分布模式实际上不受异烟肼的影响。这表明异烟肼治疗不会显著干扰通过磺胺二甲嘧啶进行的常规乙酰化表型分析。